VST Bio

VST Bio is a preclinical-stage biotech translating Yale-discovered technologies into novel antibody therapies for diseases driven by vascular leak, such as stroke, ARDS, and sepsis. Its lead candidate, VB-001, is a dual-acting antibody designed to normalize vascular integrity and reduce inflammation, aiming to dramatically limit tissue damage. The company plans to initiate clinical trials in 2026, targeting a significant unmet need in stroke where most patients are ineligible for current standard-of-care therapies.

Humanized monoclonal antibodies targeting Syndecan-2 (Sdc2) to dually regulate injury-induced vascular permeability and inflammation, without affecting normal vascular function.

The competitive landscape in acute stroke neuroprotection is challenging with a history of failures, but also underscores the significant unmet need. VST Bio's differentiated mechanism and extended treatment window position it against other late-stage neuroprotective agents and anti-edema therapies. In broader vascular leak indications, it may face competition from companies targeting angiopoietin/Tie2, VEGF, or other inflammatory pathways.